FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00145314 |
Recruitment Status :
Completed
First Posted : September 5, 2005
Last Update Posted : January 14, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Colorectal Cancer | Drug: FLOX (5-fluorouracil/folinic acid/oxaliplatin) Drug: FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab Drug: FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 571 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | 5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial. |
Study Start Date : | May 2005 |
Actual Primary Completion Date : | May 2009 |
Actual Study Completion Date : | August 2010 |
Arm | Intervention/treatment |
---|---|
Active Comparator: A
FLOX: 5-fluorouracil/folinic acid/oxaliplatin; Nordic Regimen; given continuosly
|
Drug: FLOX (5-fluorouracil/folinic acid/oxaliplatin)
FLOX every 2nd week |
Experimental: B
FLOX: 5-fluorouracil/folinic acid/oxaliplatin and cetuximab
|
Drug: FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab
FLOX every 2nd week Cetuximab weekly |
Experimental: C
FLOX given intermittently and maintenance cetuximab
|
Drug: FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab
FLOX every 2nd week for 8 cycles. Stop of FLOX until progression then FLOX is reintroduced. Cetuximab weekly. |
- To compare efficacy, as measured by time to disease progression, of treatment with cetuximab in combination with the FLOX regimen compared to FLOX alone, in first- line treatment of patients with metastatic cororectal cancer [ Time Frame: Every 4th cycle ]
- To measure response rates, response duration, secondary surgical curative resection frequency, safety profile, overall survival and quality of life in the treatment groups. [ Time Frame: Every 2nd week (safety profile) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 74 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Histology and staging disease:
- Histological proven adenocarcinoma of the colon or rectum;
- At least one measurable metastatic disease
- If only one metastatic lesion and no S-CEA elevation, histology is mandatory;
- Availability of tumour sample for EGFR assessment.
General conditions:
- Age >18 and < 75 years;
- WHO performance status: life expectancy of more than 3 months;
- Adequate haematological function
- Adequate renal and hepatic functions
- Written informed consent
Exclusion Criteria:
Prior therapy:
- No prior chemotherapy for advanced/metastatic disease;
- No adjuvant chemotherapy the last 6 months before inclusion;
- No previous oxaliplatin;
Prior or current history:
- No current indication for resection with a curative intent;
- No evidence of CNS metastasis;
- No current infection, unresolved bowel obstruction or subobstruction, uncontrolled Crohn's disease or ulcerative colitis;
- No current history of chronic diarrhoea;
- No peripheral neuropathy;
- No other serious illness or medical conditions (including contraindication to 5 FU e.g.: angor, myocardial infarction within 6 months, contraindications to monoclonal antibodies);
- No past or concurrent history of malignant neoplasm other than colorectal adenocarcinoma within the past five years, except curatively treated non melanoma skin cancer or in situ carcinoma of the cervix;
Concomitant treatments:
- No concomitant (or within 4 weeks before randomisation) administration of any other experimental drug under investigation;
- No concurrent treatment with any other anti-cancer therapy;
Other:
- Not pregnant, no breast feeding
- Fertile patients must use adequate contraceptives
- Not include patients clearly intending to withdraw from the study if not randomised in the willing arm or patients who cannot be regularly followed up for psychological, social, familiar or geographic reasons.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00145314
Norway | |
The Nordic Colorectal Cancer Biomodulation Group | |
Oslo, Norway, NO-0407 |
Principal Investigator: | Kjell M. Tveit, MD, PhD | Professor at Ullevål University Hospital, Norway |
Responsible Party: | Kjell M. Tveit, MD, PhD, The Nordic Colorectal Cancer Biomodulation Group |
ClinicalTrials.gov Identifier: | NCT00145314 |
Other Study ID Numbers: |
Nordic VII EudraCT no.: 2005-000117-34 |
First Posted: | September 5, 2005 Key Record Dates |
Last Update Posted: | January 14, 2011 |
Last Verified: | January 2011 |
Metastatic colorectal cancer FLOX Cetuximab |
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Leucovorin Folic Acid Fluorouracil Oxaliplatin |
Cetuximab Levoleucovorin Antimetabolites Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents, Immunological Antidotes Protective Agents Vitamin B Complex Vitamins Micronutrients |